Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.42 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919530 | 0.83 | PSEN1 (0.41) | CNR2NR2E1PSEN1PSEN2APH1B | |
| SCHEMBL1673249 | 0.76 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1672519 | 0.73 | KDM4E (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6919404 | 0.73 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11901925 | 0.71 | P2RX7 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11916715 | 0.71 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11902125 | 0.70 | ADRB2 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11901871 | 0.70 | P2RX7 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11901978 | 0.70 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6920278 | 0.70 | ALDH1A1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2011048525-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, GSAP | CNR2 1193/4885USP36 980/4885CNR1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.